
BLSM Stock Forecast & Price Target
BLSM Analyst Ratings
Bulls say
BlossomHill Therapeutics is a promising biotech company, with a current market value of $30/share and a focus on developing drugs for NSCLC and other cancers. However, there are potential risks associated with regulatory approval and competition, and concerns about side effects for their lead drug, BH-30643. While they have potential for growth and mergers/acquisitions, profitability is not yet achieved and future capital raising may be necessary.
Bears say
BlossomHill Therapeutics is an early-stage biotech company with a business strategy focused on targeted "precision oncology" therapeutics aimed at developing differentiated small molecule medicines for cancer treatment. While the company's lead candidates show potential in addressing clinically validated and novel molecular targets, the competitive nature of the oncology market and the need for significant sales and marketing infrastructure may prove challenging for the company to overcome. Furthermore, the company's reliance on small molecule inhibitors and its focus on highly mutated cancers may limit its potential for widespread success in the market. Thus, there may be limited upside for shareholders, and the company's stock may continue to underperform.
This aggregate rating is based on analysts' research of Blossomhill Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BLSM Analyst Forecast & Price Prediction
Start investing in BLSM
Order type
Buy in
Order amount
Est. shares
0 shares